PriceTargets.com logo

Acceleron Pharma - XLRN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$178.75 As of 11/22/2021 01:00 AM ET
+0 (0.00%)
Get New Acceleron Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XLRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XLRN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Acceleron Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $178.75.

This chart shows the closing price for XLRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Acceleron Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/6/2021Jefferies Financial GroupInitiated CoverageHold$180.00
10/4/2021Raymond JamesDowngradeStrong-Buy ➝ Market Perform
10/1/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$180.00
10/1/2021BarclaysDowngradeOverweight ➝ Equal Weight$150.00 ➝ $180.00
9/30/2021CowenDowngradeOutperform ➝ Market Perform$173.00 ➝ $180.00
9/30/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$180.00
9/30/2021HC WainwrightDowngradeBuy ➝ Neutral$168.00 ➝ $180.00
9/30/2021Piper SandlerDowngradeOverweight ➝ Neutral$146.00 ➝ $180.00
9/30/2021Leerink PartnersBoost TargetMarket Perform$148.00 ➝ $180.00
9/27/2021Royal Bank of CanadaBoost TargetSector Perform$113.00 ➝ $179.00
8/5/2021Piper SandlerBoost TargetOverweight$143.00 ➝ $146.00
7/19/2021Wolfe ResearchInitiated CoverageBuy$183.00
6/27/2021Leerink PartnersReiterated RatingHold
6/24/2021OppenheimerBoost TargetOutperform$141.00 ➝ $160.00
6/15/2021Leerink PartnersReiterated RatingHold
3/29/2021The Goldman Sachs GroupReiterated RatingNeutral$132.00
3/29/2021Leerink PartnersReiterated RatingOutperform ➝ Market Perform$148.00
3/23/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$148.00
3/22/2021The Goldman Sachs GroupReiterated RatingNeutral$132.00 ➝ $132.00
3/11/2021Wolfe ResearchInitiated CoverageOutperform$200.00
3/1/2021CitigroupBoost TargetBuy$137.00 ➝ $171.00
2/26/2021Piper SandlerBoost TargetOverweight$130.00 ➝ $143.00
2/26/2021Morgan StanleyBoost TargetOverweight$135.00 ➝ $145.00
2/26/2021Leerink PartnersBoost TargetOutperform$138.00 ➝ $148.00
1/29/2021JPMorgan Chase & Co.Boost TargetOverweight$133.00 ➝ $153.00
1/19/2021Raymond JamesBoost TargetStrong-Buy$155.00 ➝ $160.00
1/19/2021HC WainwrightBoost TargetBuy$148.00 ➝ $168.00
12/21/2020BarclaysBoost TargetOverweight$133.00 ➝ $150.00
12/16/2020Morgan StanleyBoost TargetOverweight$130.00 ➝ $135.00
11/16/2020OppenheimerBoost TargetOutperform$120.00 ➝ $131.00
11/6/2020Morgan StanleyBoost TargetOverweight$125.00 ➝ $130.00
11/6/2020Leerink PartnersBoost TargetOutperform$134.00 ➝ $138.00
11/6/2020HC WainwrightBoost TargetBuy$137.00 ➝ $148.00
10/13/2020Morgan StanleyBoost TargetOverweight$123.00 ➝ $125.00
9/29/2020HC WainwrightReiterated RatingBuy
8/24/2020Raymond JamesInitiated CoverageStrong-Buy$155.00
8/7/2020Credit Suisse GroupBoost TargetOutperform$134.00 ➝ $135.00
8/7/2020Leerink PartnersBoost TargetOutperform$132.00 ➝ $134.00
7/15/2020Morgan StanleyBoost TargetOverweight$122.00 ➝ $123.00
7/7/2020Piper SandlerLower TargetOverweight$135.00 ➝ $130.00
6/26/2020Leerink PartnersBoost TargetOutperform$127.00 ➝ $132.00
6/25/2020CowenBoost TargetOutperform$121.00 ➝ $140.00
6/25/2020Royal Bank of CanadaBoost TargetSector Perform$72.00 ➝ $99.00
6/25/2020Credit Suisse GroupBoost TargetOutperform$123.00 ➝ $134.00
6/25/2020OppenheimerReiterated RatingBuy$115.00 ➝ $120.00
6/2/2020CitigroupBoost TargetBuy$136.00 ➝ $137.00
5/12/2020Leerink PartnersBoost Target$104.00 ➝ $127.00
5/12/2020BarclaysReiterated RatingBuy$116.00
5/12/2020JPMorgan Chase & Co.Boost TargetOverweight$108.00 ➝ $118.00
5/12/2020OppenheimerBoost TargetOutperform$112.00 ➝ $115.00
5/8/2020Credit Suisse GroupBoost TargetOutperform$99.00 ➝ $123.00
5/4/2020HC WainwrightReiterated RatingBuy$137.00
4/6/2020Piper SandlerReiterated RatingBuy$135.00
4/6/2020Credit Suisse GroupReiterated RatingBuy$99.00
4/6/2020OppenheimerBoost TargetOutperform$108.00 ➝ $112.00
4/6/2020HC WainwrightBoost TargetBuy$128.00 ➝ $137.00
4/6/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$73.00
3/10/2020HC WainwrightLower TargetBuy$129.00 ➝ $128.00
3/2/2020CitigroupLower TargetBuy$138.00 ➝ $136.00
2/27/2020BarclaysInitiated CoverageOverweight$107.00
2/18/2020HC WainwrightBoost TargetBuy$90.00 ➝ $129.00
2/11/2020OppenheimerBoost TargetOutperform$79.00 ➝ $112.00
2/3/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$52.00 ➝ $122.00
1/28/2020OppenheimerBoost Target$57.00 ➝ $79.00
1/28/2020CowenBoost Target$78.00 ➝ $109.00
1/28/2020Piper SandlerBoost TargetOverweight$73.00 ➝ $135.00
1/28/2020The Goldman Sachs GroupReiterated RatingNeutral$47.00 ➝ $81.00
1/28/2020Royal Bank of CanadaBoost TargetSector Perform$72.00
1/28/2020Credit Suisse GroupBoost TargetOutperform ➝ Outperform$58.00 ➝ $99.00
1/28/2020CitigroupBoost TargetBuy ➝ Buy$75.00 ➝ $138.00
1/27/2020Royal Bank of CanadaReiterated RatingHold$47.00
1/22/2020CitigroupBoost TargetBuy$52.00 ➝ $75.00
12/17/2019Morgan StanleyBoost TargetEqual Weight$48.00 ➝ $52.00
12/10/2019HC WainwrightInitiated CoverageBuy$88.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/4/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Acceleron Pharma logo
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $178.75
Low: $178.75
High: $178.75

50 Day Range

MA: $176.25
Low: $172.08
High: $179.68

52 Week Range

Now: $178.75
Low: $108.82
High: $189.99

Volume

N/A

Average Volume

572,759 shs

Market Capitalization

$10.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Acceleron Pharma?

The following Wall Street sell-side analysts have issued stock ratings on Acceleron Pharma in the last year: StockNews.com.
View the latest analyst ratings for XLRN.

What is the current price target for Acceleron Pharma?

0 Wall Street analysts have set twelve-month price targets for Acceleron Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Acceleron Pharma in the next year.
View the latest price targets for XLRN.

What is the current consensus analyst rating for Acceleron Pharma?

Acceleron Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for XLRN.

What other companies compete with Acceleron Pharma?

Other companies that are similar to Acceleron Pharma include argenx, BioNTech, Biogen, Moderna and Neurocrine Biosciences. Learn More about companies similar to Acceleron Pharma.

How do I contact Acceleron Pharma's investor relations team?

Acceleron Pharma's physical mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company's listed phone number is (617) 649-9200 and its investor relations email address is [email protected]. The official website for Acceleron Pharma is www.acceleronpharma.com. Learn More about contacing Acceleron Pharma investor relations.